Inactive Instrument

Cassiopea S.p.A. Stock price

Equities

SKIN

IT0005108359

Pharmaceuticals

Dynamic Chart
Cassiopea S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyphens Pharma Pte. Ltd., Enters into Exclusive License and Supply Agreements with Cassiopea S.p.A. for Exclusive Rights to Develop and Commercialize Winlevi in 10 Countries Across Southeast Asia CI
Cassiopea Gets SIX Swiss Exchange Nod to Delist After Cosmo Pharmaceuticals Buyback MT
Cassiopea To Delist From Swiss Bourse In March After Takeover By Cosmo Pharmaceuticals MT
Cassiopea to Delist Shares from Swiss Bourse After Takeover by Cosmo MT
Cosmo Closes Public Exchange Offer For Cassiopea After Amassing 97% Stake MT
Cosmo Pharmaceuticals Secures Over 93% Stake in Cassiopea at Tender Closing MT
Cassiopea S.p.A.(SWX:SKIN) dropped from Swiss Performance Index (Price Return) CI
Cosmo Pharmaceuticals N.V. completed the acquisition of an additional 49.9% stake in Cassiopea S.p.A. from a group of shareholders in a mergers of equal transaction for approximately CHF 160 million. CI
Cosmo Pharmaceuticals to Start Additional Acceptance Period in Cassiopea Offer MT
Cosmo Pharmaceuticals Wins Shareholders Nod For Cassiopea Stake Deal MT
Cosmo Pharmaceuticals Raises Cassiopea Stake To Over 87% MT
Cassiopea's Partner Launches Winlevi Acne Treatment In US MT
Cosmo Pharmaceuticals N : Initiates Public Exchange Offer For Cassiopea MT
Cosmo Pharmaceuticals Intends to Acquire Cassiopea CI
More news
Managers TitleAgeSince
Chief Executive Officer 56 15-03-31
Director of Finance/CFO 58 14-12-31
Chief Tech/Sci/R&D Officer 72 16-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 15-03-31
Director of Finance/CFO 58 14-12-31
Director/Board Member - -
More insiders
Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is on the topical treatment of acne, androgenic alopecia (''AGA'') and genital warts. Its portfolio comprises four clinical candidates, such as Winlevi, Breezula, CB-06-01 and CB-06-02, for which the Company owns the worldwide rights. These product candidates are based on three chemical entities (''NCE''). They target unmet medical needs and addressable opportunities in the medical dermatology market. The main shareholder of the Company is Cosmo Pharmaceuticals SA.
More about the company
  1. Stock
  2. Equities
  3. Stock Cassiopea S.p.A. - Swiss Exchange